Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 8, 2021

View Archived Issues

AstraZeneca patents SLC12A5 activators

Minghui Pharmaceutical scientists synthesize new JAK inhibitors

Evotec presents ISR pathway modulators

MCT4 is a prognostic marker in anaplastic thyroid cancer

Merck KGaA and Ryvu Therapeutics divulge new ACSS2 inhibitors

Sichuan Haisco Pharmaceutical describes new JAK inhibitors

SG-3-00802 shows encouraging preclinical activity in combination with anti-PD-1 therapy

HC-070 attenuates stress-related excessive sensitivity to aversion and apathy for reward in mice

Stealth's SBT-272 shows promise in murine model of ALS

Development of cell-penetrating asymmetric siRNAs for treating androgenetic alopecia

NK-92 with truncated PD-1 shows enhanced therapeutic effects

Dapiglutide attenuates intestinal insufficiency in vivo

Aileron Therapeutics' ALRN-6924 shows preclinical activity against acute radiation injury

Rare APOE variant gives insight into Alzheimer's pathogenesis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...